Financial Journalist
// by Nina Trentmann
// by Nina Trentmann
// by Nina Trentmann
// by Nina Trentmann
// by Nina Trentmann
// by Nina Trentmann
// by Nina Trentmann
Bayer AG’s failure to identify weaknesses in Merck & Co.’s over the counter drug business before it bought it in 2014 sets a problematic precedent for its latest acquisition, an M&A expert told me today. Why? Read my piece for the Wall Street Journal’s CFO Journal.
// by Nina Trentmann
// by Nina Trentmann
// by Nina Trentmann
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
